Zoetis Inc.· ZTS

🇺🇸 US · LargeSP500NYSE

Healthcare Drug Manufacturers - Specialty & Generic Website

Price: $73.60
Day: -2.92%
Mkt Cap: $30.86B
52W Range: $71.00 – $152.12
Volume: 5.65M
Beta: 0.73

5D Framework

Company Overview

Snapshot of fundamentals, performance, and 5D scores.

5D scores: Quality 3.5, Peers 3.5, Valuation 5.0, Analysts 3.0, Holdings 3.7 (out of 5)
Market: $73.60 a share, market cap $30.86B, -51.5% over 12 months
Company: Healthcare · Drug Manufacturers - Specialty & Generic, 14,500 employees, NYSE

Blog

Company Profile

Business fundamentals and company information

Business Description

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Key Details

CEO

Kristin C. Peck

Employees

14,500

Headquarters

Parsippany, NJ, US

IPO Date

Feb 2013

Exchange

New York Stock Exchange

Phone

973 822 7000

Healthcare · Drug Manufacturers - Specialty & Generic

SEC filings

10-KFeb 12, 2026 10-QAug 6, 2026 8-KAug 6, 2026

Price Performance

Recent price action and historical returns

Price Performance

$73.60

Historical Returns

Price performance over time

1 Day

-2.92%

5 Day

-4.54%

1 Month

+1.29%

3 Months

-10.46%

6 Months

-38.92%

YTD

-41.50%

1 Year

-51.50%

3 Years

-60.38%

5 Years

-64.84%

10 Years

+43.89%

Revenue Analysis

How the business makes money, by product and geography

2025 revenue · 6 products

Revenue to Profit Flow · 2025

How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A) → Operating Income → Tax / Interest → Net Income.

Learn how to read flow diagrams

5D Framework

Five lenses on the stock. Click any card to dive deeper.

Quality

Business fundamentals

3.5/5

Adequate

View Details

Peers

Competitive position

3.5/5

Adequate

View Details

Valuation

Model-based valuation (vs. price)

5.0/5

Well below estimate

View Details

Analysts

Wall Street sentiment

3.0/5

Neutral

View Details

Holdings

Smart money flows

3.7/5

Bullish

View Details

How to read these dimensions

The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.